Torres-Lobatón A

Language: Spanish
References: 19
Page: 177-187
PDF size: 391.69 Kb.

ABSTRACT

Malignant ovarian germ cell tumors (MOGCT) are extremely aggressive and rapidly growing neoplasms, with a peak incidence occurring in adolescent girls and young women. Its incidence in Mexico is three times higher than the observed in Western countries and the United States. Dysgerminoma, immature teratoma, yolk salc tumor, and mixed germ cell tumors make up more than 90% of all MOGCT.

REFERENCES

1. Berek SJ, Friedlander M, Hacker FN. Cáncer de células germinales y otros cánceres ováricos no epiteliales. En: Oncología Ginecológica de Berek & Hacker. 5ª ed. Madrid: Lippincott Williams & Wilkins. Philadelphia, 2010;509-535.

2. Weinberg EL, Lurain RJ, Singh KD, Schink CJ. Survival and reproductive outcomes in women treated for malignant ovarian germ cell tumors. Gynecol Oncol 2011;121: 285-289.

3. Low HJJ, Ilancheran A, Ng SJ. Malignant ovarian germcell tumours. Best Practand Res Clin Obstet Gynaecol 2012;26:347-355.

4. Escudero MP, Bañuelos FJ, Quijano CF, et al. Informe clínico de 90 casos de tumores germinales de ovario. GAMO 2005;4:97-101.

5. Mangili G, Sigismondi C, Gadducci A, Cormio G, Scollo P, Tateo S, et at. Outcome and Risk factors for Recurrence in malignant Ovarian Ger, Cell tumors. Int J Gynecol Cancer 2011;21:1414-1420.

6. Frecuencia relativa de las neoplasias ováricas malignas 1993-1995. En: Registro Histopatológico de Neoplasias. México: Dirección de Epidemiología SSA, 1997;11-13.

7. Torres LA, Kippes GP, Bassaure ER, Oliva PJC, Morales PMA, Quintero BG, et al. Neoplasias germinales malignas del ovario. Incidencia en el Servicio de Oncología del Hospital General de México. GAMO 2007;6:38-41.

8. Vazquez I, Rustin SJG. Current controversies in the management of germ cell ovarian tumours. Curr Opin Oncol. 2013;25:539-545.

9. Pectasides E. Germ cell tumours of the ovary. Cancer Treatment Reviews. 2008; 34: 427-441.

10. Cheng L, Roth ML, Zhang Sh, Wang M, Morton JM, Zheng W. et al. KIT Gene Mutation And Amplification in Dysgerminoma of the Ovary. Cancer 2011; 117:2096-2103.

11. He Li, Ding H, Wang HJ, LiL,Yu HY, Huang L et al. Overexpression of Karyopherin 2 in Human Ovarian Malignant Germ Cell Tumor Correlates with poor Prognosis. PLOS ONE/www.plosone.org.2012;7:Issue 9/e42992. p.1-11.

12. Gershenson M D. Current advances in the management of malignant germ cell and sex cord-stromal tumors of the ovary. Gynecol Oncol. 2012:125:515-517.

13. Parkinson A Ch, Hatcher MH, Ajithkumar VTh.Management of Malignant Ovarian Germ Cell tumors. Obstet Gynecol Surv. 2011;66:507-514.

14. Kumar S,Shah JP,Bryant CS Imudia AN, Cote ML, Ali-Fehmi R, et al. The revalence and prognostic impact of lymph node metastasis in malignant germ cell tumors of the ovary. Gynecol Oncol. 2008; 110:125-132.

15. Assad VD, Nogueira RA, Maluf CF, Buzaid C. Ovario. Tumores Germinales En:Manual de Oncología Clínica de Brasil de Antonio Carlos Buzaid y Fernando Cortait Maluf. Ed. Dendrix. Sao Paulo Brasil 2013;265-273.

16. NCCN. Cancer network. Guidelines version 1.2013. Less common Ovarian Histopathologies. National Comprehensive Cancer Network 2013;1-3.

17. Mahdi H, Hanna R, Seward S, Swemsen R, Tamin H, Morris R et al. Prognostic impact of lymphadenectomy in clinically early-stage ovarian malignant germ cell tumor. Gyneco Oncol Abstracts 2011;120: S85.

18. Lee WCh, Song JM, Park TS, Ki YE, Lee JS, Lee HK, Ryu SK, et al. Residual tumor after salvage surgery is the major risk factors for primary treatment failure in malignant ovarian germ cell tumors: a retrospective study of single institution. WJ Surg Oncol 2011;9:123-31.

19. Weinberg EL, Lurain RJ, Singh KD, Schink CJ. Survival and reproductive outcomes in women treated for malignant ovarian germ cell tumors. Gynecol Oncol 2011;121: 285-289.